TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10403584

Group type: EXPERIMENTAL
Intervention: Low-GI diet (51% CHO, 23% fat, 43 GI units)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-mono high-GI diet (42% CHO, 35% fat, 59 GI units)
Number of subjects: 21

Group type: COMPARATOR
Intervention: High-GI diet (53% CHO, 21% fat, 63 GI units)
Number of subjects: 21
Study: 7673961

Group type: EXPERIMENTAL
Intervention: Patients with relapsing remitting multiple sclerosis experiencing a relapse.
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group of patients matched for age, sex, and degree of disability who did not experience clinical exacerbations during the same period.
Number of subjects: 89
Study: 2405895

Group type: EXPERIMENTAL
Intervention: isoflurane
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: halothane
Number of subjects: 44
Study: 31900245

Group type: EXPERIMENTAL
Intervention: Laparoscopic supracervical hysterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endometrial ablation
Number of subjects: 0
Study: 31313336

Group type: EXPERIMENTAL
Intervention: Urinary cadmium (U‐Cd)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Blood cadmium (B‐Cd)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Urinary cadmium (U‐Cd) at 95th percentile cut-off
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Blood cadmium (B‐Cd) at 95th percentile cut-off
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Urinary cadmium (U‐Cd) at 90th percentile cut-off
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Blood cadmium (B‐Cd) at 90th percentile cut-off
Number of subjects: 288
Study: 28542868

Group type: EXPERIMENTAL
Intervention: 15 ml lidocaine 2%
Number of subjects: 16

Group type: COMPARATOR
Intervention: 15 ml saline
Number of subjects: 16
Study: 25906348

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 1573

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1573
Study: 23869370

Group type: EXPERIMENTAL
Intervention: Immediate loading (test group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional loading (control group)
Number of subjects: 30
Study: 21585062

Group type: EXPERIMENTAL
Intervention: Acu-moxibustion treatment (12 weeks, once every other day, main acupoints: Feishu, Geshu, Ganshu, Pishu, Shenshu; moxibustion applied for about 3 min each time)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication group (oral Acitretin capsules, 20 mg/d for 12 weeks)
Number of subjects: 60
Study: 19175613

Group type: EXPERIMENTAL
Intervention: 40 mg eletriptan
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-specific treatment
Number of subjects: 41
Study: 17313602

Group type: EXPERIMENTAL
Intervention: Angio-Seal STS device
Number of subjects: 206

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 206
Study: 14742356

Group type: EXPERIMENTAL
Intervention: Aprotinin regimen with a bolus of 1 x 10(6) kallikrein inhibiting units (KIU) before CPB, 1 x 10(6) KIU in the priming solution, and a continuous infusion of 250,000 KIU/h during CPB.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Heparin management according to Hepcon HMS Plus.
Number of subjects: 200
Study: 11476127

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15-60 mg/day)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Venlafaxine (75-375 mg/day, twice a day)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 157
Study: 9782221

Group type: EXPERIMENTAL
Intervention: Dirithromycin (D) 500 mg once daily for 5 days
Number of subjects: 46
Study: 8156516

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CY) 2400 mg per M2 as a single-day dose and vincristine (VCR) 1.4 mg per M2 given on Day 1 after CY
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CY) 2400 mg per M2 as a single-day dose and vincristine (VCR) 1.4 mg per M2 given on Day 9 after CY
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (standard doses of chemotherapy)
Number of subjects: 108
Study: 3058555

Group type: EXPERIMENTAL
Intervention: De‐Nol (colloidal bismuth subcitrate) for eight weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 31094587

Group type: EXPERIMENTAL
Intervention: Device-measured sedentary behaviour
Number of subjects: 233
Study: 30762217

Group type: EXPERIMENTAL
Intervention: Arthroscopic suprapectoral intraosseous implant-free biceps tenodesis (ASIIBT) with Cobra Guide (CG)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Suture anchors (SA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Interference screws (IS)
Number of subjects: 58
Study: 30144894

Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 28543286

Group type: EXPERIMENTAL
Intervention: Crossover from rhythm control to rate control (594 patients)
Number of subjects: 4060

Group type: EXPERIMENTAL
Intervention: Crossover from rate control to rhythm control (248 patients)
Number of subjects: 4060

Group type: COMPARATOR
Intervention: Crossover from rhythm control to rate control
Number of subjects: 4060

Group type: COMPARATOR
Intervention: Crossover from rate control to rhythm control
Number of subjects: 4060
Study: 26625506

Group type: EXPERIMENTAL
Intervention: Financial incentive ($8 per medication per month)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Financial incentive ($8 per medication per month) in diabetics
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control group (usual care) in diabetics
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Financial incentive ($8 per medication per month) in nondiabetics
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control group (usual care) in nondiabetics
Number of subjects: 337
Study: 23847058

Group type: EXPERIMENTAL
Intervention: QIV
Number of subjects: 3094

Group type: COMPARATOR
Intervention: TIV-Vic
Number of subjects: 3094

Group type: COMPARATOR
Intervention: TIV-Yam
Number of subjects: 3094
Study: 20498402

Group type: EXPERIMENTAL
Intervention: Consolidation radiotherapy (RT)
Number of subjects: 807

Group type: COMPARATOR
Intervention: No consolidation radiotherapy (RT)
Number of subjects: 807
Study: 18951296

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0
Study: 17348307

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 100
Study: 14638564

Group type: EXPERIMENTAL
Intervention: Self-management program (3 group sessions and telephone follow-up)
Number of subjects: 211
Study: 10843169

Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (run-in)
Number of subjects: 16
Study: 8855526

Group type: EXPERIMENTAL
Intervention: Pulse-spray thrombolysis plus angioplasty
Number of subjects: 20

Group type: COMPARATOR
Intervention: Surgical thrombectomy
Number of subjects: 20
Study: 1735858

Group type: EXPERIMENTAL
Intervention: Collagel (human collagen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healon (sodium hyaluronate)
Number of subjects: 0
Study: 6369583

Group type: EXPERIMENTAL
Intervention: Postoperative nasogastric drainage avoided completely in 40 patients (nonintubated group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine postoperative nasogastric aspiration
Number of subjects: 52
Study: 30498835

Group type: EXPERIMENTAL
Intervention: Six-month reduced calorie diet at two protein levels
Number of subjects: 67
Study: 27502800

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium with aromatherapy (2% rose essential oil)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg/im)
Number of subjects: 100
Study: 24337978

Group type: EXPERIMENTAL
Intervention: QGC001 (10, 50, 125, 250, 500, 750, 1,000, and 1,250 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: QGC001
Number of subjects: 56
Study: 22395187

Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with 2.0 g/L FOS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with 3.0 g/L FOS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Commercially available milk-based infant formula
Number of subjects: 4

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 4
Study: 20384757

Group type: EXPERIMENTAL
Intervention: Erbium 1,550‐nm fractional laser at 10 mJ
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Erbium 1,550‐nm fractional laser at 40 mJ
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Erbium 1,550‐nm fractional laser (both dosages)
Number of subjects: 15
Study: 18399898

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MSNF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16036387

Group type: EXPERIMENTAL
Intervention: Magnesium (2 g/h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenoterol (270 microg/h) + Verapamil (0.2 mg/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium (2 mmol) in vitro
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (0.25 mg/ml) in vitro
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%) in vitro
Number of subjects: 0
Study: 12750099

Group type: EXPERIMENTAL
Intervention: Macular Computerized Psychophysical Test (MCPT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Amsler grid
Number of subjects: 108
Study: 10550454

Group type: EXPERIMENTAL
Intervention: Estradiol 25 mg/day
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Estradiol 50 mg/day
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Estradiol 75 mg/day
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Estradiol (all doses)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study: 8905799

Group type: EXPERIMENTAL
Intervention: Erythromycin 1,200 mg/day for 10 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 12
Study: 1991182

Group type: EXPERIMENTAL
Intervention: Smoking (4 cigarettes an hour)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-smoking (abstained for seven days or more)
Number of subjects: 8
Study: 6140938

Group type: EXPERIMENTAL
Intervention: ICI 118551 20 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ICI 118551 50 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30907785

Group type: EXPERIMENTAL
Intervention: Pressure-free, adhesive bone conduction device
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional bone conduction device
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 13
Study: 28303364

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (500 mL daily for one week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (for one week after washout)
Number of subjects: 30
Study: 25209368

Group type: EXPERIMENTAL
Intervention: Phosphate binding medication adherence intervention
Number of subjects: 112
Study: 23473040

Group type: EXPERIMENTAL
Intervention: 1 mA anodal transcranial direct current stimulation (tDCS) for 10 min
Number of subjects: 13
Study: 21844061

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium phosphate (1.6 mg/kg per day for 3 days)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 18971132

Group type: EXPERIMENTAL
Intervention: CO(2) pneumoperitoneum with 4% oxygen
Number of subjects: 22

Group type: COMPARATOR
Intervention: CO(2) pneumoperitoneum (control)
Number of subjects: 22
Study: 16492611

Group type: EXPERIMENTAL
Intervention: Hypertensive patients (93.5% newly diagnosed, 6.5% treated)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 301
Study: 12971032

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg as intact tablets with water
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg as tablets crushed in acidic juice
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ketoconazole 200 mg as intact tablets
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gastric emptying rate measured by radiolabeled technetium
Number of subjects: 18
Study: 11685350

Group type: EXPERIMENTAL
Intervention: ICU rehabilitation package (6-week self-help program including information and exercise)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Routine follow-up of ward visits and ICU clinic appointments
Number of subjects: 61
Study: 9234872

Group type: EXPERIMENTAL
Intervention: Active ultrasound device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 60
Study: 8218758

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg each morning)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Famotidine (40 mg at night time)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 60
Study: 3578422

Group type: EXPERIMENTAL
Intervention: 5000 U sodium heparin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 7500 U sodium heparin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10000 U sodium heparin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heparin neutralization activity
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fibrinopeptide A
Number of subjects: 24
Study: 29125719

Group type: EXPERIMENTAL
Intervention: Obiltoxaximab 4 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obiltoxaximab 8 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obiltoxaximab 16 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obiltoxaximab 20 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obiltoxaximab 24 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obiltoxaximab (all doses)
Number of subjects: 0
Study: 27537996

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab (both IXEQ2W and IXEQ4W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study: 24439682

Group type: EXPERIMENTAL
Intervention: Individual cognitive behavioural treatment
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural treatment
Number of subjects: 168

Group type: COMPARATOR
Intervention: Treatment as usual improved with Smith's norms
Number of subjects: 168
Study: 23275372

Group type: EXPERIMENTAL
Intervention: Grape polyphenols (PPs) 2 g/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (PCB)
Number of subjects: 38
Study: 21645041

Group type: EXPERIMENTAL
Intervention: Music intervention (self-selected soothing music for 30 minutes)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Chair rest (quiet sitting for 30 minutes)
Number of subjects: 54
Study: 17932377

Group type: EXPERIMENTAL
Intervention: Particle-filtered air
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nonfiltered air
Number of subjects: 21
Study: 16814663

Group type: EXPERIMENTAL
Intervention: Metyrapone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12636461

Group type: EXPERIMENTAL
Intervention: CPR first with 3 minutes of basic CPR prior to defibrillation (n = 104)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care with immediate defibrillation (n = 96)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CPR first with 3 minutes of basic CPR prior to defibrillation (n = 64, response times longer than 5 minutes)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care with immediate defibrillation (n = 55, response times longer than 5 minutes)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CPR first with 3 minutes of basic CPR prior to defibrillation (n = 40, response times up to 5 minutes)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care with immediate defibrillation (n = 41, response times up to 5 minutes)
Number of subjects: 200
Study: 10758987

Group type: EXPERIMENTAL
Intervention: Original images
Number of subjects: 71

Group type: COMPARATOR
Intervention: Compression ratio 6:1
Number of subjects: 71

Group type: COMPARATOR
Intervention: Compression ratio 10:1
Number of subjects: 71

Group type: COMPARATOR
Intervention: Compression ratio 16:1
Number of subjects: 71
Study: 8716494

Group type: EXPERIMENTAL
Intervention: Horizontal grid pattern intervention using black insulation tapes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (other types of dementia)
Number of subjects: 10
Study: 1306606

Group type: EXPERIMENTAL
Intervention: SpermPrep filtration method
Number of subjects: 148

Group type: COMPARATOR
Intervention: Double sperm wash (SW) procedure
Number of subjects: 148
Study: 3948092

Group type: EXPERIMENTAL
Intervention: Chorionic Villus Sampling (CVS)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control (no CVS)
Number of subjects: 202
Study: 30457230

Group type: EXPERIMENTAL
Intervention: PVP group
Number of subjects: 54

Group type: COMPARATOR
Intervention: HA group
Number of subjects: 54
Study: 26689304

Group type: EXPERIMENTAL
Intervention: Integrative cognitive‐affective therapy for BN (ICAT‐BN)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Enhanced cognitive behavior therapy (CBT‐E)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 80
Study: 25485197

Group type: EXPERIMENTAL
Intervention: Borage and echium seed oils
Number of subjects: 28
Study: 23000708

Group type: EXPERIMENTAL
Intervention: Calcium‐incorporated titanium implants
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control titanium implants
Number of subjects: 60
Study: 20496965

Group type: EXPERIMENTAL
Intervention: Computerized disability-specific abuse assessment intervention at Time 1 (T1) and Time 2 (T2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group completing the assessment intervention at Time 2 (T2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computerized disability-specific abuse assessment intervention
Number of subjects: 0
Study: 17038684

Group type: EXPERIMENTAL
Intervention: artesunate-sulfamethoxypyrazine-pyrimethamine
Number of subjects: 606

Group type: COMPARATOR
Intervention: artemether-lumefantrine
Number of subjects: 606
Study: 14610474

Group type: EXPERIMENTAL
Intervention: Exhaled nitric oxide (eNO) measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rank regression analysis
Number of subjects: 0
Study: 10910838

Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg/kg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 8718563

Group type: EXPERIMENTAL
Intervention: Cilazapril (1 mg single dose at the end of HD session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontreatment period (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0
Study: 1572445

Group type: EXPERIMENTAL
Intervention: HDM injections
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 18
Study: 3917653

Group type: EXPERIMENTAL
Intervention: Bestatin (30 mg/day) and FT‐207 (0.6 g/day p.o.) after 1/2MF'C regimen (mitomycin C 2 mg and cytosine arabinoside 20 mg i.v. twice a week for 3 weeks, FT‐207 400 mg/day i.v. for 3 weeks)
Number of subjects: 162

Group type: COMPARATOR
Intervention: FT‐207 alone after 1/2MF'C regimen
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Bestatin
Number of subjects: 162
Study: 31691253

Group type: EXPERIMENTAL
Intervention: NeuroSENSE EEG monitor
Number of subjects: 75
Study: 31566694

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) plus usual obstetric care
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo ultrasound treatment plus usual obstetric care
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual obstetric care only
Number of subjects: 400
Study: 28919733

Group type: EXPERIMENTAL
Intervention: CET + IMT
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: CET
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (free walking)
Number of subjects: 81
Study: 25882973

Group type: EXPERIMENTAL
Intervention: Zirconia ceramic cantilever fixed dental prostheses (ZC-CFDPs)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Metal ceramic cantilever fixed dental prostheses (MC-CFDPs)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both ZC-CFDPs and MC-CFDPs
Number of subjects: 21
Study: 24273968

Group type: EXPERIMENTAL
Intervention: Bushen Yijing Decoction (BYD), tamoxifen tablet (TT), Licorzine Capsule (LC), and Vitamin E Soft Capsule (VESC)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Bushen Yijing Decoction (BYD), Licorzine Capsule (LC), and Vitamin E Soft Capsule (VESC)
Number of subjects: 450

Group type: COMPARATOR
Intervention: tamoxifen tablet (TT), Licorzine Capsule (LC), and Vitamin E Soft Capsule (VESC)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group 1
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Treatment group and control group 1
Number of subjects: 450
Study: 22102213

Group type: EXPERIMENTAL
Intervention: Tecnis ZCB00
Number of subjects: 22

Group type: COMPARATOR
Intervention: Acrysof SN60WF
Number of subjects: 22
Study: 19393261

Group type: EXPERIMENTAL
Intervention: Low-level random-dot kinematograms (RDKs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-level random-dot kinematograms (RDKs)
Number of subjects: 0
Study: 16839836

Group type: EXPERIMENTAL
Intervention: 20% lipid/heparin infusion at a rate of 1.5 mL/min for 6 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline/heparin infusion at a rate of 1.5 mL/min for 6 hours
Number of subjects: 8
Study: 12632618

Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope
Number of subjects: 50

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 50